Metabolic syndrome

• Metabolic syndrome is a cluster of five metabolic abnormalities: central (abdominal) obesity, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose. A person has the syndrome when at least 3 of the 5 are present.
• It is not a single disease with one cause. It is a convenient label for a set of risk factors that cluster in the same person and together multiply the risk of type 2 diabetes mellitus and atherosclerotic cardiovascular disease.
• Insulin resistance, driven mainly by excess visceral fat, links the components: it worsens glucose handling, raises triglycerides and lowers HDL cholesterol, and contributes to hypertension and inflammation.
• The first treatment for every patient is lifestyle: a 7% to 10% weight loss over 12 months, regular physical activity, and a diet rich in vegetables, fruit, legumes, whole grains, nuts and fish. Drug therapy then treats each component according to its own guideline and the patient's overall cardiovascular risk.
• Associated conditions include type 2 diabetes mellitus, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD), polycystic ovary syndrome and obstructive sleep apnoea.

By the end of this page you should be able to:

1. State the five harmonized criteria for metabolic syndrome, list the agreed cut points, and explain how the International Diabetes Federation (IDF) and the American Heart Association / National Heart, Lung, and Blood Institute (AHA/NHLBI) definitions differ.
2. Explain how visceral adiposity leads to insulin resistance, atherogenic dyslipidaemia, hypertension and chronic inflammation, and name the adipokines and cytokines involved.
3. Quantify the excess risk of type 2 diabetes mellitus and atherosclerotic cardiovascular disease that metabolic syndrome confers. ^[1]
4. Recognise the conditions that cluster with metabolic syndrome (type 2 diabetes, cardiovascular disease, MASLD, polycystic ovary syndrome, obstructive sleep apnoea).
5. Plan stepwise management: lifestyle goals, component-by-component drug treatment, when to start a statin and which blood pressure target to use, and the place of GLP-1 receptor agonists and bariatric surgery in obesity.
6. Explain honestly why "metabolic syndrome" is a debated concept, and how care is adapted in low-resource settings.

The modern, harmonized definition was agreed in a joint interim statement of the International Diabetes Federation (IDF), the National Heart, Lung, and Blood Institute (NHLBI), the American Heart Association (AHA), the World Heart Federation, the International Atherosclerosis Society and the International Association for the Study of Obesity.^[3] Their consensus was deliberate: no single component is obligatory, and 3 abnormal findings out of 5 qualify.^[3] A single set of cut points is used for the laboratory and pressure components; waist circumference, the measure with the strongest links to ethnicity and to body-fat distribution, was left open to national or regional cut points pending further work.^[3]

Before the 2009 harmonized statement, the two most influential definitions came from the International Diabetes Federation (IDF, 2005) and the AHA/NHLBI (2005/2009 update).^[2][3] The Alberti 2009 meeting identified the key difference as the way central obesity is handled: in the IDF definition abdominal obesity is an obligatory component with lower, ethnic-specific waist cut points, whereas the AHA/NHLBI definition does not require central obesity and uses the higher >40 in / >35 in thresholds.^[3] Both require 3 of 5 abnormal findings. The table below summarizes the practical differences that still appear in clinics and papers today.^[2]

In practice the harmonized 2009 consensus (any 3 of 5, regional waist cut points accepted) is now the most widely used.^[3] For a world reader, the important point is that a South Asian, Chinese or Japanese patient can have significant metabolic risk at waist sizes well below the 102 cm / 88 cm table value, and ethnic-specific thresholds should be used where they exist.^[3][5]

Metabolic syndrome is a useful teaching label, not a disease with a single cause. The 2018 AHA/ACC cholesterol guideline lists it as a "risk-enhancing factor", not as a separate indication for treatment; intensive lifestyle therapy is described as the primary intervention for metabolic syndrome in all age groups.^[4] Critics (and supporters) of the concept point out that the five components overlap and that the clustering may not identify risk beyond its parts; in 2005 the AHA and NHLBI themselves described the definition as close to the modified ATP III definition used earlier.^[2] Clinically the right conclusion is that naming the syndrome should never replace assessing and treating each risk factor on its own evidence.

Metabolic syndrome is common, rising, and no longer confined to affluent populations. Using National Health and Nutrition Examination Survey (NHANES) data, the prevalence in US adults rose from 25.3% to 34.2% by 2012.^[1] Almost 40% of people in their sixth decade have metabolic syndrome, and prevalence climbs with age.^[1] Worldwide, more than a billion people are estimated to have the syndrome.^[6] In low- and middle-income countries prevalence is rising fast as urbanization changes diets and physical activity.^[6] Children are affected too: about 3% of children and 5% of adolescents globally had metabolic syndrome in 2020.^[1]

Roughly 85% of people with type 2 diabetes mellitus also meet the criteria for metabolic syndrome.^[2] Metabolic syndrome increases the risk of atherosclerotic cardiovascular disease about two-fold and of type 2 diabetes mellitus about five-fold compared with people without it.^[1] Between 22% and 24% of men and women respectively now have the syndrome in the USA.^[2]

There is no single cause. Metabolic syndrome reflects the interaction of genetics, epigenetics, environment and behaviour.^[2] The initiating driver in most patients is sustained positive energy balance leading to visceral fat accumulation; high caloric intake has been identified as the main cause of visceral fat accumulation.^[1] Releases from enlarged visceral adipose tissue (tumour necrosis factor alpha, leptin, adiponectin, resistin, plasminogen activator inhibitor-1, interleukin-6 and others) alter insulin signalling and produce systemic inflammation.^[1][2] Genetics contribute: variants in FTO and other loci influence adiposity and metabolic traits, and intrauterine and early-life nutrition programme later risk.^[2]

Insulin resistance itself can be acquired (typically from visceral obesity and inactivity) or have a genetic basis, and can be caused by insulin receptor defects, impaired signalling and defective beta-cell secretion.^[1]

• Central (visceral) obesity, particularly with an "apple-shaped" distribution rather than subcutaneous "pear-shaped" fat.^[2]
• Physical inactivity and prolonged sedentary time.^[2][6]
• An energy-dense diet high in refined carbohydrate, saturated fat, sodium and processed food, and low in fruit, vegetables, legumes and whole grains.^[1]
• Family history of obesity or type 2 diabetes, and ethnic groups with high cardiometabolic risk at lower body size (for example South Asian, Chinese and Japanese populations).^[1][5]
• Sleep apnoea and sleep deprivation, which can promote the development of the syndrome.^[1]
• Advancing age, although the syndrome now occurs in children and adolescents.^[1]

The components of metabolic syndrome are not five separate diseases happening at once. They share a common pathway that runs visceral fat -> insulin resistance -> dyslipidaemia -> chronic inflammation -> endothelial dysfunction and hypertension. Understanding this pathway lets you reason out the clinical picture instead of memorizing a list.

Visceral adipose tissue is an active endocrine organ. Its adipocytes and infiltrating immune cells release free fatty acids directly into the portal circulation, plus adipokines and cytokines: leptin, adiponectin, resistin, angiotensinogen (renin-angiotensin system), plasminogen activator inhibitor-1, interleukin-6, tumour necrosis factor alpha, and acute-phase reactants such as C-reactive protein.^[2] Visceral fat, rather than subcutaneous fat, is the more important contributor to insulin resistance, precisely because its lipolysis drains free fatty acids to the liver through the splanchnic circulation.^[2]

Under normal conditions, a rise in glucose triggers pancreatic beta-cell insulin secretion; insulin then drives glucose into liver, muscle and adipose tissue and suppresses lipolysis and gluconeogenesis. In insulin resistance, tissues are less sensitive to this signal, producing compensatory hyperinsulinaemia and, eventually, fasting hyperglycaemia when compensation fails.^[1][2]

Free fatty acids released by insulin-resistant adipose tissue worsen the problem: they alter the insulin signalling cascade in muscle (reducing insulin receptor substrate-1 associated PI3K activity and GLUT4 translocation, so glucose uptake falls) and promote hepatic gluconeogenesis and lipid synthesis.^[2] Beta-cell lipotoxicity then compounds the fall in insulin.^[2]

The same free fatty acids explain the dyslipidaemia. High free fatty acids increase hepatic triglyceride and cholesterol ester synthesis and very-low-density lipoprotein (VLDL) production; VLDL activates cholesterol ester transfer protein, which moves triglyceride into HDL and increases HDL clearance, while triglyceride-rich LDL is hydrolysed to small, dense LDL particles.^[2] That is why metabolic syndrome dyslipidaemia is high triglycerides, low HDL cholesterol and small dense LDL rather than isolated LDL elevation.

Insulin resistance also drives hypertension, through loss of insulin's vasodilatory effect, free-fatty-acid-induced vasoconstriction (reactive oxygen species scavenging nitric oxide), increased sympathetic activity and renin-mediated sodium retention.^[2] It creates a prothrombotic state and increases serum viscosity.^[2] Insulin resistance can be estimated clinically with the homeostatic model assessment (HOMA-IR), with optimal cut points around 2.0 in men and 2.5 in women in published meta-analysis, should a quantification be useful.^[2]

The pathways above converge on a pro-inflammatory state, reflected in raised interleukin-6, tumour necrosis factor alpha, high-sensitivity C-reactive protein and fibrinogen, with increased monocyte Toll-like receptor activity.^[2] Interleukin-6 from macrophages and adipocytes stimulates hepatic acute-phase proteins (C-reactive protein), raises fibrinogen (prothrombotic), and promotes vascular cell adhesion and local renin-angiotensin activation; tumour necrosis factor alpha impairs insulin signalling by inactivating insulin receptors and stimulates hepatic lipolysis, raising free fatty acids.^[2] Raised leptin and lowered adiponectin, a protective adipokine, are part of the same picture.^[2]

Endothelial dysfunction (from increased plasminogen activator inhibitor-1, adipokines and low nitric oxide), vascular resistance and stiffening, and hypertension then lead to left ventricular hypertrophy, cardiomyopathy, renal impairment, endothelial dysfunction and accelerated atherosclerosis.^[1] Dyslipidaemia and hypertension together drive symptomatic ischaemic heart disease.^[1] Patients with metabolic syndrome have more than a two-fold higher incidence of cardiovascular events (myocardial infarction, stroke, heart failure), independent of age, sex and diabetes.^[1]

There is no single "symptom of metabolic syndrome"; patients present through its components or its complications. Many have no symptoms at all and are identified by opportunistic measurement of waist circumference, blood pressure, lipids and fasting glucose.^[1]

History-taking should probe lifestyle (diet, physical activity, sleep, alcohol, smoking), family history of premature atherosclerotic cardiovascular disease, and symptoms of diabetes (polyuria, polydipsia, polyphagia), of polycystic ovary syndrome in women, and of obstructive sleep apnoea (snoring, witnessed apnoeas, daytime somnolence).^[1]

Examination: measure blood pressure correctly, measure waist circumference (a required screening step^[1]), and look for markers of insulin resistance and dyslipidaemia: acanthosis nigricans, xanthomas and xanthelasma; overweight or obvious central adiposity. None of these signs alone confirms the syndrome. (See the criteria table above.)

Because metabolic syndrome is a risk pattern, its "differential" is essentially the list of secondary and mimicking causes of its parts: renal parenchymal or renovascular disease, endocrine disorders (hypothyroidism, Cushing syndrome, acromegaly, pheochromocytoma), polycystic ovary syndrome.^[1] Hypothyroidism in particular can produce hypertension, dyslipidaemia and obesity and so closely mimics the syndrome.^[1] Hepatic steatosis (MASLD) is better classified as an associated condition than a mimic, because the metabolic drivers overlap.

Initial investigations follow from the five criteria and the risk they carry.^[1]

• Fasting plasma glucose and HbA1c for dysglycaemia and type 2 diabetes.
• Fasting lipid panel (triglycerides, HDL cholesterol, LDL cholesterol) for atherogenic dyslipidaemia.
• Serum creatinine and electrolytes, and urinalysis for renal involvement and microalbuminuria.
• Liver enzymes; consider MASLD evaluation if enzymes are raised or risk is high (fatty change on ultrasound, non-invasive fibrosis scores such as FIB-4, elastography where available).^[5]
• Thyroid stimulating hormone where hypothyroidism is suspected.^[1]
• C-reactive protein, uric acid and liver function tests in selected patients to assess associated metabolic conditions.^[1]

Cardiovascular risk should be quantified: the 2019 AHA/ACC primary prevention framework and pooled cohort equations are used to calculate 10-year atherosclerotic cardiovascular disease risk, and metabolic syndrome itself counts as a risk-enhancing factor that can move a patient towards statin therapy.^[4] In asymptomatic patients at significant risk, coronary artery calcium scoring can refine the estimate.^[1]

Diagnosis is clinical: 3 of 5 criteria (the table above). There is no single severity score for the syndrome; instead each component is graded and treated on its own scale (blood pressure stage, HbA1c, ASCVD risk category). Where insulin resistance itself is quantified, HOMA-IR cut points of about 2.0 in men and 2.5 in women have been reported for predicting metabolic syndrome.^[2] Note that fasting insulin measurement is not recommended for routine large-scale screening; waist circumference is used as the practical surrogate.^[2]

The primary goal is to identify and treat each risk factor and to reduce cardiovascular and diabetic complications.^[1] In all age groups, lifestyle therapy is the primary intervention for metabolic syndrome.^[4] Drug therapy follows, component by component, guided by existing cardiovascular, blood pressure, lipid and diabetes guidelines rather than by the syndrome label itself.^[4] Have the patient co-decide: shared decision making and adherence matter more than the exact pill, because multiple drugs are usually needed and regimens are complex.^[1]

• Physical activity: the AHA/ACC recommend 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity physical activity per week.^[1] The MASLD literature gives a similar prescription of at least 150 minutes of moderate (or 75 minutes of vigorous) activity per week and gradual weight loss of up to 1 kg per week through a 500 to 1000 kcal daily deficit.^[5]
• Diet: a diet rich in vegetables, fruit, legumes, whole grains, nuts and fish reduces cardiovascular risk; avoid or limit processed foods, refined carbohydrates, sodium, saturated fat and, where relevant, alcohol and smoking.^[1]
• Sleep: treat obstructive sleep apnoea and protect sleep duration and quality; sleep apnoea can contribute to the development of metabolic syndrome.^[1]
• Psychosocial: social support and stress management matter for sustaining lifestyle change.^[1]
• Self-monitoring: weight, dietary intake, activity logs and, where useful, home blood pressure and glucose records.

Activity and diet are the two interventions that improve every component at once (blood pressure, glucose, triglycerides, HDL and weight), which is why they are the foundation.^[1]

Dyslipidaemia. Fibrate or statin choices must follow local guidance. For atherogenic dyslipidaemia the priority is LDL-cholesterol reduction for cardiovascular prevention, then triglycerides. The 2018 AHA/ACC cholesterol guideline makes metabolic syndrome a risk-enhancing factor: in adults 40 to 75 years without diabetes and with intermediate 10-year risk (7.5% to 19.9%), the presence of metabolic syndrome favours initiating a statin.^[4] Other statin triggers, applied by risk:^[4]

• LDL cholesterol 190 mg/dL (4.9 mmol/L) or higher, regardless of calculated risk: high-intensity statin. ^[4]
• Age 40 to 75 with diabetes and LDL cholesterol 70 mg/dL (1.8 mmol/L) or higher: start a moderate-intensity statin, with high-intensity reasonable if multiple risk factors or age 50 to 75. ^[4]
• Age 40 to 75 with 10-year ASCVD risk 7.5% or higher: moderate-intensity statin. ^[4]
• In established atherosclerotic cardiovascular disease: high-intensity statin aiming to lower LDL cholesterol by 50% or more. ^[4]

HDL-cholesterol-raising with niacin or CETP inhibitors has not been shown to reduce events and should not be the goal; the role of fibrates is adjunctive for high triglycerides (target under 150 mg/dL / 1.7 mmol/L), and fibrates in combination with statins to reduce cardiovascular risk are not recommended.^[5] For LDL reduction, ezetimibe and, in selected high-risk patients, PCSK9 inhibitors are second-line after a maximally tolerated statin.^[5] In MASLD, statins are safe (including when aminotransferases are modestly raised) and first-line for cardiovascular risk.^[5]

Hypertension. Treat using standard thresholds: blood pressure 140/90 mmHg or higher in all patients, and 130/80 mmHg or higher in diabetes or with ASCVD risk of 10% or more, aiming for 120-129/70-79 mmHg where tolerated.^[5] Choice of agents follows comorbidity: renin-angiotensin system blockade (ACE inhibitor or angiotensin receptor blocker) is preferred when albuminuria, ischaemic heart disease or heart failure is present; thiazide-like diuretics and calcium-channel blockers are standard alternatives or additions; in decompensated cirrhosis (if MASLD has progressed) ACE inhibitors and angiotensin receptor blockers are generally avoided.^[1][5]

Dysglycaemia and insulin resistance. Metformin, DPP-4 inhibitors, GLP-1 receptor agonists and pioglitazone are the drug classes used for insulin resistance and dysglycaemia in metabolic syndrome.^[1] Pioglitazone improves insulin sensitivity and liver histology in MASLD but is associated with weight gain, fluid retention, heart failure and other adverse effects and should be used cautiously.^[5] Where hypertension is present, treat to the thresholds above.

GLP-1 receptor agonists and bariatric surgery in obesity. In obese patients GLP-1 receptor agonists (and the GLP-1/GIP receptor agonist tirzepatide) improve glycaemia, body weight and liver fat/content, and GLP-1 receptor agonists are preferred adjunctive therapy when BMI is 27 kg/m2 or above with comorbidities or 30 kg/m2 or above without.^[5] Liraglutide and semaglutide improve resolution of steatohepatitis in trials, and tirzepatide has superior metabolic efficacy; GLP-1 receptor agonists are licensed for diabetes and obesity.^[5] Bariatric surgery is the most effective single therapy for severe obesity-related metabolic syndrome and is recommended for BMI 40 kg/m2 or above, or BMI 35 kg/m2 or above with other comorbidities; it produces sustained weight loss, improves liver histology and reduces cardiovascular events, and needs long-term follow-up for nutritional, surgical and psychiatric complications.^[1][5]

Monitoring. Recheck lipids 4 to 12 weeks after starting or changing a statin dose, then every 3 to 12 months as needed, and use the percentage LDL-cholesterol reduction as the audit target rather than a single number alone.^[4]

Metabolic syndrome has no complications of its own beyond those of its components, but it predicts them strongly.

• Type 2 diabetes mellitus. Metabolic syndrome confers about a five-fold excess risk of type 2 diabetes, and conversely about 85% of people with type 2 diabetes also meet the criteria for metabolic syndrome.^[2] The excess risk is about five-fold compared with people without the syndrome.^[1]
• Atherosclerotic cardiovascular disease. The excess risk is about two-fold: more than double the rate of myocardial infarction, stroke and heart failure, independent of age, sex and diabetes.^[1]
• MASLD. Excess visceral fat with insulin resistance drives hepatic fat infiltration; steatotic liver disease has become the most common chronic liver disease worldwide and 30% of adults are affected; it can progress to steatohepatitis, fibrosis and cirrhosis, and liver cancer. Cardiovascular disease, not liver disease, is the leading cause of death in MASLD, so cardiovascular risk reduction is central to its care.^[5]
• Polycystic ovary syndrome. This is best seen as an overlapping condition: insulin resistance, central adiposity and atherogenic dyslipidaemia cluster in both. Women with PCOS should be screened for the syndrome's components and for cardiometabolic risk.^[1]
• Obstructive sleep apnoea. Present in many patients; it is both a contributor to and a consequence of metabolic syndrome. Three months of continuous positive airway pressure can lower blood pressure in moderate to severe sleep apnoea and may partially reverse metabolic abnormalities.^[1]

Prognosis depends on how many components are present and on cardiovascular complications already incurred. The syndrome is not fixed: weight loss, activity and treatment of components can reverse much or all of it, including liver fat, dyslipidaemia and hypertension. Without intervention, conversion to type 2 diabetes and a rising burden of cardiovascular disease is the expected trajectory.^[1][2]

• Children and adolescents. Metabolic syndrome exists in this group (about 3% of children, 5% of adolescents) and is increasing. Causes in the young are often severe or monogenic obesity, so check diet, activity, family history and possible genetic or endocrine disease; management is lifestyle-centred and multidisciplinary, not a prescription list.^[1]
• Pregnancy. Cardiometabolic risk accumulates across pregnancies; women with gestational diabetes or hypertensive disorders are at higher lifetime risk of metabolic syndrome and type 2 diabetes and need postpartum screening and long-term follow-up.
• Older adults. Prevalence is highest in the sixth and seventh decades, but lifestyle therapy still slows or reverses components; drug choices in the frail should balance benefit against polypharmacy, hypotension and hypoglycaemia.
• Low-resource and LMIC settings. See below.

Metabolic syndrome can be diagnosed and treated without expensive technology.

• Measurements that matter: a tape measure for waist circumference, a sphygmomanometer and a fasting glucose or HbA1c where available measure the majority of the risk. HOMA-IR and coronary calcium scoring are not needed for care.
• Prevalence is rising rapidly in low- and middle-income countries as urbanization drives changes in diet and activity.^[6] Workplace- and community-based lifestyle programmes that use local social support, managers and cultural context are more effective than imported generic leaflets.^[6]
• Lifestyle first remains the most cost-effective therapy: cohort and low-cost interventions (walking groups, reduced sugar intake, salt reduction, weight loss) improve every component.
• Use affordable generics: metformin, standard statins and thiazide-like diuretics or calcium-channel blockers cover the bulk of dysglycaemia and dyslipidaemia in the syndrome. ACE inhibitors or angiotensin receptor blockers are used for albuminuria, ischaemic heart disease or heart failure when available and affordable.
• Where labs are scarce, treat empirically on clinical grounds: treat hypertension with available agents, counsel on weight and activity for all, and refer for glucose testing where prevalence is high.
• Refer for severe or secondary hypertension, suspected Cushing syndrome, marked hypertriglyceridaemia causing pancreatitis, and possible bariatric surgical centres where appropriate.
• Stepwise care: start with lifestyle and one or two drugs, re-check, then intensify. Polypharmacy should be kept to what the patient can afford and adhere to.

• Type 2 diabetes mellitus
• Atherosclerotic cardiovascular disease and cardiovascular risk assessment
• Hypertension
• Dyslipidaemia (hypertriglyceridaemia and low HDL cholesterol)
• Obesity
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Polycystic ovary syndrome
• Obstructive sleep apnoea
• Insulin resistance